We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Pre-clinical evaluation of a P. berghei-based whole-sporozoite malaria vaccine candidate.
- Authors
Mendes, António M.; Reuling, Isaie J.; Andrade, Carolina M.; Otto, Thomas D.; Machado, Marta; Teixeira, Filipa; Pissarra, Joana; Gonçalves-Rosa, Nataniel; Bonaparte, Dolores; Sinfrónio, João; Sanders, Mandy; Janse, Chris J.; Khan, Shahid M.; Newbold, Chris I.; Berriman, Matthew; Lee, Cynthia K.; Wu, Yimin; Ockenhouse, Christian F.; Sauerwein, Robert W.; Prudêncio, Miguel
- Abstract
Whole-sporozoite vaccination/immunization induces high levels of protective immunity in both rodent models of malaria and in humans. Recently, we generated a transgenic line of the rodent malaria parasite P. berghei (Pb) that expresses the P. falciparum (Pf) circumsporozoite protein (PfCS), and showed that this parasite line (PbVac) was capable of (1) infecting and developing in human hepatocytes but not in human erythrocytes, and (2) inducing neutralizing antibodies against the human Pf parasite. Here, we analyzed PbVac in detail and developed tools necessary for its use in clinical studies. A microbiological contaminant-free Master Cell Bank of PbVac parasites was generated through a process of cyclic propagation and clonal expansion in mice and mosquitoes and was genetically characterized. A highly sensitive qRT-PCR-based method was established that enables PbVac parasite detection and quantification at low parasite densities in vivo. This method was employed in a biodistribution study in a rabbit model, revealing that the parasite is only present at the site of administration and in the liver up to 48 h post infection and is no longer detectable at any site 10 days after administration. An extensive toxicology investigation carried out in rabbits further showed the absence of PbVac-related toxicity. In vivo drug sensitivity assays employing rodent models of infection showed that both the liver and the blood stage forms of PbVac were completely eliminated by Malarone® treatment. Collectively, our pre-clinical safety assessment demonstrates that PbVac possesses all characteristics necessary to advance into clinical evaluation. Malaria: Pre-clinical characterization of transgenic malaria vaccine PbVac is a transgenic malaria parasite expressing circumsporozoite antigen from the human parasite Plasmodium falciparum. PbVac elicits neutralizing P. falciparum antibodies and can infect human hepatocytes but not erythrocytes, suggesting that humans would be non-permissive. Miguel Prudêncio and colleagues at the Institute of Molecular Medicine in Lisbon perform a detailed in vivo analysis and toxicology of PbVac. Extensive biodistribution analysis using a highly sensitive qPCR in non-permissive rabbit hosts shows PbVac are present at the initial bite site early on with later appearance in the liver, but by day 10 is undetectable. Importantly no PbVac could be detected in the blood at any time-point. PbVac was well tolerated with no apparent pathological signatures. In permissive mouse hosts PbVac could be effectively eliminated from both the blood and liver and could thereby act as a potential clinical 'safety net' in the event of an erythrocytic stage or persistence in the liver.
- Subjects
PLASMODIUM berghei; SPOROZOITES; MALARIA vaccines; PLASMODIUM falciparum; CIRCUMSPOROZOITE protein
- Publication
NPJ Vaccines, 2018, Vol 3, Issue 1, pN.PAG
- ISSN
2059-0105
- Publication type
Article
- DOI
10.1038/s41541-018-0091-3